American Society of Hirudotherapy

Mutagenesis studies toward understanding allostery in thrombin

Research article published in Biochemistry (2009)

Last Updated: November 1, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDrug DevelopmentSalivary PharmacologyQureshi et al. · Biochemistry, 2009

Abstract

The binding of thrombomodulin (TM) to exosite-1 and the binding of Na(+) to 225-loop allosterically modulate the catalytic activity and substrate specificity of thrombin. To determine whether the conformation of these two cofactor-binding loops are energetically linked to each other and to the active site, we rationally designed two thrombin mutants in which either the 70-80 loop of exosite-1 or the 225-loop of the Na(+)-binding site was stabilized by an engineered disulfide bond. This was possible by replacing two residues, Arg-67 and Ile-82, in the first mutant and two residues, Glu-217 and Lys-224, in the second mutant with Cys residues. These mutants were expressed in mammalian cells as monomeric molecules, purified to homogeneity and characterized with respect to their ability to bind TM and Na(+) by kinetic and direct binding approaches. The Cys-67/Cys-82 mutant did not bind TM and exhibited a normal amidolytic activity, however, the activity of Cys-217/Cys-224 was dramatically impaired, though TM interacted with this mutant with >20-fold elevated K(D) to partially restore its activity. Both mutants exhibited approximately 2-3-fold higher K(D) for interaction with Na(+), and neither mutant clotted fibrinogen or activated protein C in the presence of TM. Both mutants interacted with heparin with a normal affinity. These results suggest that, while exosite-2 of thrombin is an independent cofactor binding-site, both Na(+)-binding and exosite-1 are energetically linked. Further studies with the fluorescein labeled Cys-195 mutant of thrombin revealed that the catalytic residue of thrombin is modulated by Na(+), but TM has no effect on the conformation of this residue.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, N.I.H., Extramural
Indexed MeSH termsAllosteric RegulationAnimalsCatalytic DomainCattleCricetinaeDisulfidesEnzyme ActivationHeparinHumansKineticsModels, MolecularMutagenesisMutant ProteinsMutationPeptide HydrolasesSodiumThrombin

Summary

Disulfide-locking thrombin's exosite-1 70-80 loop or the Na+-binding 225-loop showed both mutants lost fibrinogen clotting and TM-dependent protein C activation and bound Na+ more weakly, indicating that Na+ binding and exosite-1 are energetically linked while exosite-2 is independent.

Context

This study used rationally designed thrombin mutants with engineered disulfide bonds to probe whether exosite-1 (thrombomodulin binding), the Na+-binding 225-loop, and the active site are energetically linked, finding that Na+-binding and exosite-1 are conformationally coupled while exosite-2 (heparin binding) functions independently. Thrombin is the primary target of hirudin from the leech secretome. The study involves no leech-derived molecules, hirudin, or secretome components whatsoever — it is a protein engineering/kinetics study using mammalian cell–expressed mutants.

Citation

Reference (Vancouver style)

Qureshi SH, Yang L, Manithody C, Iakhiaev AV, Rezaie AR. Mutagenesis studies toward understanding allostery in thrombin. Biochemistry. 2009;48(34):8261-8270. doi:10.1021/bi900921t. PMID: 19640005

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.